FDA Output, October 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in October 2026. Updated October 31.
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in October 2026. Updated October 31.
Jon Kamerman, Philips’ Enterprise Healthcare Solutions Leader for its Ambulatory Monitoring and Diagnostics business, discusses his organization’s focus on a patient-monitoring ecosystem that can help detect cardiac disease earlier and improve care continuity.
Medtech companies, weighed down by depressed stock prices and market challenges, are under intense pressure to step out of their comfort zones and make bets on innovation that will drive their future. Excerpted from our recent feature article, Despite Headwinds, A Nascent Medtech Rebound Is Fueling M&A.